GCA
CLVS

Greenwood Capital Associates’s Clovis Oncology, Inc. CLVS Stock Holding History

Greenwood Capital Associates’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-6,981
Closed -$317K – 228
2018
Q2 		$317K Buy
6,981
+1,408
+25% +$68.5K 0.07% 132
2018
Q1 		$294K Sell
5,573
-32
-0.6% -$1.87K 0.07% 140
2017
Q4 		$381K Buy
5,605
+996
+22% +$69.6K 0.09% 133
2017
Q3 		$380K Sell
4,609
-876
-16% -$69.4K 0.09% 125
2017
Q2 		$514K Buy
5,485
+212
+4% +$13K 0.13% 104
2017
Q1 		$336K Sell
5,273
-1,995
-27% -$121K 0.09% 135
2016
Q4 		$323K Buy
+7,268
New +$256K 0.09% 127

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Greenwood Capital Associates's CLVS Position: Q3 2018 in Review

Greenwood Capital Associates sold out of Clovis Oncology, Inc. (CLVS) in Q3 2018, closing a stake of 6,981 shares — an estimated $317K sold.

Greenwood Capital Associates first reported a position in CLVS in Q4 2016 and held it in 7 quarters. The position peaked at $514K in Q2 2017. 192 funds tracked by Wall St. Rank hold CLVS as of Q3 2018.

  • Greenwood Capital Associates reported no remaining Clovis Oncology, Inc. position as of Q3 2018 after selling out during the quarter.
  • Greenwood Capital Associates sold 6,981 Clovis Oncology, Inc. shares in Q3 2018, an estimated $317K.
  • Greenwood Capital Associates first reported a position in Clovis Oncology, Inc. in Q4 2016 and held it in 7 quarters.
  • Greenwood Capital Associates's Clovis Oncology, Inc. position peaked at $514K in Q2 2017.
  • 192 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2018.

Based on Greenwood Capital Associates's 13F filing for Q3 2018, filed 13 Nov 2018.